Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Metrics to compare | KURN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKURNPeersSector | |
---|---|---|---|---|
P/E Ratio | −82.0x | −2.9x | −0.7x | |
PEG Ratio | −2.59 | −0.03 | 0.00 | |
Price/Book | 12.1x | 1.7x | 2.6x | |
Price / LTM Sales | 13.9x | 6.7x | 3.2x | |
Upside (Analyst Target) | - | 205.8% | 44.1% | |
Fair Value Upside | Unlock | 9.5% | 8.2% | Unlock |